Therapeutic peptides: molecular signaling networks in orthopaedic medicine — VialBase Research
TB-500 and TB-4 promote angiogenesis and tissue repair in preclinical models
- TB-500 and TB-4 promote angiogenesis and tissue repair in preclinical models
- BPC-157, TB-500, and GHK-Cu promote integrin-mediated extracellular matrix remodeling and fibroblast activation
- Human orthopaedic data for TB-500 are lacking
- Both TB-4 and TB-500 remain banned substances in sports
- Growth hormone secretagogues (ipamorelin, CJC-1295) activate IGF-1 signaling and satellite cell repair
Summary
Comprehensive review of therapeutic peptides in orthopaedic medicine. Evaluates wound-healing peptides (BPC-157, TB-500, GHK-Cu), growth hormone secretagogues (ipamorelin, CJC-1295, tesamorelin, sermorelin, AOD-9604), recovery-enhancing agents (epithalon, DSIP, pinealon), and neuroactive peptides (selank, semax, dihexa). Maps molecular signaling pathways including PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK.
Key Findings
- TB-500 acts through PI3K/Akt and mTOR pathways for tissue regeneration
- Promotes angiogenesis, integrin-mediated ECM remodeling, and fibroblast activation
- Preclinical evidence is promising but clinical trials are currently lacking
- Both TB-4 and TB-500 are banned by WADA, limiting clinical study in sports medicine
- The review emphasizes safety, efficacy, and responsible integration into musculoskeletal care
Relevance to TB-500
Positions TB-500 within the broader landscape of therapeutic peptides for orthopaedic applications. Confirms preclinical promise while highlighting the critical gap in human clinical data. Important context for understanding TB-500’s evidence level relative to other healing peptides. Also cross-references BPC-157, CJC-1295, Ipamorelin, and GHK-Cu.
Citation
Orthopaedic Review. 2026. PMID: 41476424